MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Akciju saraksts・Harvard Bioscience Inc

Harvard Bioscience Inc

Slēgts

SektorsVeselības aprūpe

0.66 3.13

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.64

Max

0.66

Galvenie mērījumi
By Trading Economics
Ienākumi	1.1M -1.2M
Pārdošana	141K 21M
Peļņas marža	-5.978
Darbinieki	330
EBITDA	1M 1.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+198.51% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	4M 30M
Iepriekšējā atvēršanas cena	-2.47
Iepriekšējā slēgšanas cena	0.66

Ziņu noskaņojums

By Acuity

50%

157 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

0.3 / 0.3401 Atbalsts un pretestība

Harvard Bioscience Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025. g. 31. dec. 13:01 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025. g. 31. dec. 11:10 UTC

Tirgus saruna

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025. g. 31. dec. 10:46 UTC

Tirgus saruna

Euro on Track For Strong Annual Performance -- Market Talk

2025. g. 31. dec. 10:25 UTC

Tirgus saruna

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025. g. 31. dec. 10:23 UTC

Tirgus saruna

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025. g. 31. dec. 09:33 UTC

Tirgus saruna

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Harvard Bioscience Inc Prognoze

Cenas mērķis

By TipRanks

198.51% augšup

Prognoze 12 mēnešiem

Vidējais 2 USD 198.51%

Augstākais 2 USD

Zemākais 2 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harvard Bioscience Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harvard Bioscience Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.3 / 0.3401Atbalsts un pretestība

Bearish events outweigh bullish events.

There are no events.

Noskaņojums

By Acuity

157 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.